|
시장보고서
상품코드
1424051
항기생충제 시장 점유율, 규모, 동향, 산업 분석 보고서 : 유형별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2024-2032년)Antiparasitic Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Antiprotozoals, Anthelmintics, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024- 2032 |
||||||
Polaris Market Research의 최신 조사에 따르면, 세계 항기생충제 시장 규모는 2032년까지 382억 달러에 달할 것으로 예상됩니다. 이 조사 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.
개발도상국의 신흥 시장은 항기생충제 시장에 좋은 기회를 제공합니다. 의료 인프라가 개선되고 인식이 높아짐에 따라 기생충 감염에 대한 효과적인 치료제에 대한 수요가 증가하고 있습니다. 이들 지역의 높은 감염률로 인해 제약사들은 접근하기 쉽고 저렴한 솔루션을 도입하고 시장 진입 및 확장을 위한 전략적 제휴를 구축하고 있습니다.
표적 치료는 항기생충제 시장에서 매우 중요한 기회로, 효능을 높이고 부작용을 최소화하기 위해 정확하고 맞춤화된 치료법을 제공합니다. 분자적 이해의 진보를 활용한 이러한 치료법은 특정 기생충에 초점을 맞추고 환자 치료 결과를 개선하는 혁신적인 솔루션을 제공합니다. 이러한 표적화된 접근법의 연구개발에 투자하는 제약회사는 시장을 선도할 수 있는 위치에 있습니다. 이러한 전략적 움직임은 치료 옵션의 폭을 넓히는 동시에 약물 내성 문제를 해결하는 동시에 항기생충제 개발에서 개인 맞춤형 의료의 진화에 부합하는 것입니다.
임상시험은 항기생충제 시장 형성에 있어 매우 중요한 역할을 합니다. 안전성과 유효성을 검증하는 것뿐만 아니라 엄격한 임상시험에 참여함으로써 제약 회사는 혁신가로서의 입지를 구축할 수 있습니다. 임상시험의 성공은 규제 당국의 승인을 받을 수 있을 뿐만 아니라 신뢰성을 확보하고 경쟁력을 확보할 수 있습니다. 이러한 참여는 의료 전문가들의 신뢰를 쌓고 시장 성장에 기여합니다. 또한, 이러한 임상시험은 기생충 감염과의 싸움에서 진화하는 요구에 부응하고 시장의 지속적인 확장을 보장하기 위해 사용 가능한 치료 옵션의 폭을 넓힐 수 있습니다.
합리화된 규제 경로, 신속한 승인 및 지원적 프레임워크는 제약 혁신에 도움이 되는 환경을 조성하고 있습니다. 이러한 배경은 기업들이 새로운 항기생충제를 신속하게 시장에 출시하여 중요한 의료 수요에 대응할 수 있도록 돕습니다. 규제 당국과 업계 관계자들의 협력은 효율적인 프로세스를 가능하게 하고 적시에 시장 진입을 촉진할 수 있습니다. 혁신적인 솔루션에 대한 장려와 신속한 규제 프레임워크가 결합되어 항기생충제 시장은 지속적으로 성장하고 있습니다.
항기생충제 시장 보고서 하이라이트
2023년 기생충 감염의 유행, 세계 보건 활동 및 인식의 증가로 인해 구충제 부문이 큰 시장 점유율을 차지했습니다.
2023년에는 신속하고 직접적인 대응과 병원에서의 광범위한 사용으로 인해 주사제 부문이 큰 시장 점유율을 차지했습니다.
2023년 병원 약국 부문은 의료 기관 내 환자 접근성이 용이하다는 점에서 병원 약국 부문이 큰 매출 점유율을 차지했습니다.
2023년에는 기생충 감염의 유행, 규제 환경, 연구 개발로 인해 북미 지역이 세계 시장을 장악했습니다.
이 시장은 Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Ipca Laboratories Ltd, Merck & Co., Viatris, Novartis 등 전 세계적으로 존재감을 드러내는 시장 기업들의 존재로 인해 경쟁이 치열합니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 항기생충제 시장에 관한 인사이트
- 항기생충제 시장 - 유통 채널 현황
- 항기생충제 시장 역학
- 성장 촉진요인과 기회
- 세계의 건강에 대한 대처가 제품 수요를 자극할 것으로 예측
- 기생충 감염증 만연이 항기생충제 시장 성장을 촉진할 것으로 예상
- 성장 억제요인과 과제
- 규제상 과제가 시장 성장을 저해할 가능성이 높다
- 성장 촉진요인과 기회
- PESTEL 분석
- 항기생충제 시장 유통 채널 동향
- 밸류체인 분석
- COVID-19 감염증의 영향 분석
제5장 세계의 항기생충제 시장, 유형별
- 주요 조사 결과
- 서론
- 항원충제
- 구충제
- 기타
제6장 세계의 항기생충제 시장, 투여 경로별
- 주요 조사 결과
- 서론
- 국소
- 경구
- 주사
제7장 세계의 항기생충제 시장, 유통 채널별
- 주요 조사 결과
- 서론
- 소매 약국
- 병원 약국
- 기타
제8장 세계의 항기생충제 시장, 지역별
- 주요 조사 결과
- 서론
- 항기생충제 시장 평가, 지역, 2019-2032년
- 항기생충제 시장 - 북미
- 북미 : 항기생충제 시장, 유형별, 2019-2032년
- 북미 : 항기생충제 시장, 유통 채널별, 2019-2032년
- 북미 : 항기생충제 시장, 투여 경로별, 2019-2032년
- 항기생충제 시장 - 미국
- 항기생충제 시장 - 캐나다
- 항기생충제 시장 - 유럽
- 유럽 : 항기생충제 시장, 유형별, 2019-2032년
- 유럽 : 항기생충제 시장, 유통 채널별, 2019-2032년
- 유럽 : 항기생충제 시장, 투여 경로별, 2019-2032년
- 항기생충제 시장 - 영국
- 항기생충제 시장 - 프랑스
- 항기생충제 시장 - 독일
- 항기생충제 시장 - 이탈리아
- 항기생충제 시장 - 스페인
- 항기생충제 시장 - 네덜란드
- 항기생충제 시장 - 러시아
- 항기생충제 시장 - 아시아태평양
- 아시아태평양 : 항기생충제 시장, 유형별, 2019-2032년
- 아시아태평양 : 항기생충제 시장, 유통 채널별, 2019-2032년
- 아시아태평양 : 항기생충제 시장, 투여 경로별, 2019-2032년
- 항기생충제 시장 - 중국
- 항기생충제 시장 - 인도
- 항기생충제 시장 - 말레이시아
- 항기생충제 시장 - 일본
- 항기생충제 시장 - 인도네시아
- 항기생충제 시장 - 한국
- 항기생충제 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 항기생충제 시장, 유형별, 2019-2032년
- 중동 및 아프리카 : 항기생충제 시장, 유통 채널별, 2019-2032년
- 중동 및 아프리카 : 항기생충제 시장, 투여 경로별, 2019-2032년
- 항기생충제 시장 - 사우디아라비아
- 항기생충제 시장 - 아랍에미리트
- 항기생충제 시장 - 이스라엘
- 항기생충제 시장 - 남아프리카공화국
- 항기생충제 시장 - 라틴아메리카
- 라틴아메리카 : 항기생충제 시장, 유형별, 2019-2032년
- 라틴아메리카 : 항기생충제 시장, 유통 채널별, 2019-2032년
- 라틴아메리카 : 항기생충제 시장, 투여 경로별, 2019-2032년
- 항기생충제 시장 - 멕시코
- 항기생충제 시장 - 브라질
- 항기생충제 시장 - 아르헨티나
제9장 경쟁 상황
- 확장과 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- AstraZeneca
- Bayer AG
- Cipla Limited
- Dr. Reddy's Laboratories
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline
- Ipca Laboratories Ltd
- Lupin Pharmaceuticals
- Merck & Co.
- Novartis
- Pfizer
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Viatris
- Zydus Group
The global Antiparasitic Drugs market size is expected to reach USD 38.20 billion by 2032, according to a new study by Polaris Market Research. The report "Antiparasitic Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Antiprotozoals, Anthelmintics, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Emerging markets in developing regions offer prime opportunities for the Antiparasitic Drugs Market. Improved healthcare infrastructure and heightened awareness drive demand for effective treatments against parasitic infections. With higher infection rates in these regions, pharmaceutical companies introduce accessible and affordable solutions, establishing strategic collaborations for market entry and expansion.
Targeted therapies present a pivotal opportunity in the antiparasitic drugs market, offering precise, personalized treatment for enhanced efficacy and minimized side effects. Leveraging advancements in molecular understanding, these therapies focus on specific parasites, providing innovative solutions with improved patient outcomes. Pharmaceutical companies investing in research and development of such targeted approaches position themselves for market leadership. This strategic move addresses the challenges of drug resistance while expanding treatment options, aligning with the evolving landscape of personalized medicine in antiparasitic drug development.
Clinical trials play a pivotal role in shaping the antiparasitic drugs market. Beyond validating safety and efficacy, participation in rigorous trials positions pharmaceutical companies as innovators. Successful trials not only secure regulatory approvals but also establish credibility, gaining a competitive edge. This engagement fosters confidence among healthcare professionals, contributing to market growth. Furthermore, these trials broaden the spectrum of available treatment options, meeting evolving needs in the fight against parasitic infections and ensuring sustained market expansion.
Streamlined regulatory pathways, expedited approvals, and supportive frameworks create a conducive environment for pharmaceutical innovation. This backing allows companies to swiftly bring novel antiparasitic drugs to market, addressing critical healthcare needs. Collaborative efforts between regulatory bodies and industry players enable efficient processes, fostering timely market entry. The encouragement of innovative solutions, coupled with responsive regulatory frameworks, positions the antiparasitic drugs Market for sustained growth.
Antiparasitic Drugs Market Report Highlights
In 2023, the Anthelmintics segment accounted for significant market share owing to prevalence of helminthic infections, global health initiatives, and increased awareness.
In 2023, the injectable segment accounted for significant market share owing to rapid and direct response, and wide use in hospitals.
In 2023, the hospital pharmacy segment held significant revenue share owing to easy access for patients within healthcare institutions.
In 2023, North America region dominated the global market due to prevalence of parasitic infections, regulatory environment, and research and development.
The market is highly competitive owing to the existence of market players with a global presence, including Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Ipca Laboratories Ltd, Merck & Co., Viatris, and Novartis among others.
Polaris Market Research has segmented the Antiparasitic Drugs market report based on type, route of administration, distribution channel, and region:
Antiparasitic Drugs, Type Outlook (Revenue - USD Billion, 2019 - 2032)
- Antiprotozoals
- Anthelmintics
- Others
Antiparasitic Drugs, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)
- Topical
- Oral
- Injectable
Antiparasitic Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)
- Retail Pharmacy
- Hospital Pharmacy
- Others
Antiparasitic Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- France
- Germany
- UK
- Italy
- Netherlands
- Spain
- Russia
- Asia Pacific
- Japan
- China
- India
- Malaysia
- Indonesia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Antiparasitic Drugs Market Insights
- 4.1. Antiparasitic Drugs Market - Distribution Channel Snapshot
- 4.2. Antiparasitic Drugs Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Global health initiatives are projected to spur the product demand
- 4.2.1.2. Prevalence of parasitic infections is expected to drive antiparasitic drugs market growth
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Regulatory challenges are likely to impede the market growth
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Antiparasitic Drugs Market Distribution Channel Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Antiparasitic Drugs Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 5.3. Antiprotozoals
- 5.3.1. Global Antiparasitic Drugs Market, by Antiprotozoals, by Region, 2019-2032 (USD Billion)
- 5.4. Anthelmintics
- 5.4.1. Global Antiparasitic Drugs Market, by Anthelmintics, by Region, 2019-2032 (USD Billion)
- 5.5. Others
- 5.5.1. Global Antiparasitic Drugs Market, by Others, by Region, 2019-2032 (USD Billion)
6. Global Antiparasitic Drugs Market, by Route of Administration
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 6.3. Topical
- 6.3.1. Global Antiparasitic Drugs Market, by Topical, by Region, 2019-2032 (USD Billion)
- 6.4. Oral
- 6.4.1. Global Antiparasitic Drugs Market, by Oral, by Region, 2019-2032 (USD Billion)
- 6.5. Injectable
- 6.5.1. Global Antiparasitic Drugs Market, by Injectable, by Region, 2019-2032 (USD Billion)
7. Global Antiparasitic Drugs Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 7.3. Retail Pharmacy
- 7.3.1. Global Antiparasitic Drugs Market, by Retail Pharmacy, By Region, 2019-2032 (USD Billion)
- 7.4. Hospital Pharmacy
- 7.4.1. Global Antiparasitic Drugs Market, by Hospital Pharmacy, By Region, 2019-2032 (USD Billion)
- 7.5. Others
- 7.5.1. Global Antiparasitic Drugs Market, by Others, By Region, 2019-2032 (USD Billion)
8. Global Antiparasitic Drugs Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Antiparasitic Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
- 8.3. Antiparasitic Drugs Market - North America
- 8.3.1. North America: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.3.2. North America: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3.3. North America: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.3.4. Antiparasitic Drugs Market - U.S.
- 8.3.4.1. U.S.: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.3.4.2. U.S.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3.4.3. U.S.: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.3.5. Antiparasitic Drugs Market - Canada
- 8.3.5.1. Canada: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.3.5.2. Canada.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3.5.3. Canada: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4. Antiparasitic Drugs Market - Europe
- 8.4.1. Europe: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.2. Europe.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.3. Europe: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.4. Antiparasitic Drugs Market - UK
- 8.4.4.1. UK: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.4.2. UK.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.4.3. UK: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.5. Antiparasitic Drugs Market - France
- 8.4.5.1. France: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.5.2. France.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.5.3. France: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.6. Antiparasitic Drugs Market - Germany
- 8.4.6.1. Germany: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.6.2. Germany.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.6.3. Germany: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.7. Antiparasitic Drugs Market - Italy
- 8.4.7.1. Italy: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.7.2. Italy.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.7.3. Italy: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.8. Antiparasitic Drugs Market - Spain
- 8.4.8.1. Spain: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.8.2. Spain.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.8.3. Spain: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.9. Antiparasitic Drugs Market - Netherlands
- 8.4.9.1. Netherlands: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.9.2. Netherlands.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.9.3. Netherlands: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.10. Antiparasitic Drugs Market - Russia
- 8.4.10.1. Russia: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.10.2. Russia.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.10.3. Russia: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5. Antiparasitic Drugs Market - Asia Pacific
- 8.5.1. Asia Pacific: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.2. Asia Pacific.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.3. Asia Pacific: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.4. Antiparasitic Drugs Market - China
- 8.5.4.1. China: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.4.2. China.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.4.3. China: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.5. Antiparasitic Drugs Market - India
- 8.5.5.1. India: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.5.2. India.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.5.3. India: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.6. Antiparasitic Drugs Market - Malaysia
- 8.5.6.1. Malaysia: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.6.2. Malaysia.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.6.3. Malaysia: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.7. Antiparasitic Drugs Market - Japan
- 8.5.7.1. Japan: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.7.2. Japan.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.7.3. Japan: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.8. Antiparasitic Drugs Market - Indonesia
- 8.5.8.1. Indonesia: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.8.2. Indonesia.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.8.3. Indonesia: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.9. Antiparasitic Drugs Market - South Korea
- 8.5.9.1. South Korea: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.9.2. South Korea.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.9.3. South Korea: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.6. Antiparasitic Drugs Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.6.2. Middle East & Africa.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.3. Middle East & Africa: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.6.4. Antiparasitic Drugs Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.6.4.2. Saudi Arabia.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.4.3. Saudi Arabia: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.6.5. Antiparasitic Drugs Market - UAE
- 8.6.5.1. UAE: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.6.5.2. UAE.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.5.3. UAE: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.6.6. Antiparasitic Drugs Market - Israel
- 8.6.6.1. Israel: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.6.6.2. Israel.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.6.3. Israel: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.6.7. Antiparasitic Drugs Market - South Africa
- 8.6.7.1. South Africa: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.6.7.2. South Africa.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.7.3. South Africa: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.7. Antiparasitic Drugs Market - Latin America
- 8.7.1. Latin America: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.7.2. Latin America.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.3. Latin America: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.7.4. Antiparasitic Drugs Market - Mexico
- 8.7.4.1. Mexico: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.7.4.2. Mexico.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.4.3. Mexico: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.7.5. Antiparasitic Drugs Market - Brazil
- 8.7.5.1. Brazil: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.7.5.2. Brazil.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.5.3. Brazil: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.7.6. Antiparasitic Drugs Market - Argentina
- 8.7.6.1. Argentina: Antiparasitic Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.7.6.2. Argentina.: Antiparasitic Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.6.3. Argentina: Antiparasitic Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. AstraZeneca
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Bayer AG
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Cipla Limited
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Dr. Reddy's Laboratories
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. F. Hoffmann-La Roche Ltd
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. GlaxoSmithKline
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Ipca Laboratories Ltd
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Lupin Pharmaceuticals
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Merck & Co.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Novartis
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Pfizer
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Sanofi
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. Sun Pharmaceutical Industries Ltd.
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
- 10.14. Viatris
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
- 10.15. Zydus Group
- 10.15.1. Company Overview
- 10.15.2. Financial Performance
- 10.15.3. Product Benchmarking
- 10.15.4. Recent Development
